<DOC>
	<DOCNO>NCT01812200</DOCNO>
	<brief_summary>Background : The acute coronary syndrome ( ACS ) complication coronary artery disease ( CAD ) associate increased mortality . Dual antiplatelet therapy acetylsalicylic acid ( ASA ) P2Y12 receptor antagonist clopidogrel cornerstone treatment patient advance CAD . Due delay onset action , intersubject variability resistance clopidogrel , different platelet aggregation inhibitor develop . Ticagrelor reversible P2Y12 receptor antagonist superior efficacy compare clopidogrel prevention cardiovascular death patient . Atrial fibrillation ( AF ) also associate thromboembolic event substantial mortality . Beside vitamin K antagonist ( VKA , phenprocoumon ) stroke prevention patient AF , direct factor Xa inhibitor rivaroxaban direct thrombin inhibitor dabigatran recently receive approval prophylactic treatment patient non-valvular AF . However , lack efficacy safety data combine impact antithrombotic drug patient require arterial venous thromboembolic prophylaxis due underlie co-morbidities . Study objectives : To evaluate effect ticagrelor + ASA combination dabigatran , rivaroxaban phenprocoumon steady state marker coagulation activation . The effect coagulation activation also study single dose dabigatran , rivaroxaban ticagrelor therapeutic INR phenprocoumon . Study design : A single-centre , prospective , randomize , control , analyst-blinded study three parallel-groups . Subjects receive ticagrelor + ASA combination dabigatran ( treatment A ) , rivaroxaban ( treatment B ) phenprocoumon ( treatment C ) . All IMPs administer dos indicate stroke prevention AF ACS . Markers thrombin generation platelet activation study venous blood coagulation rest state shed blood clotting system activate microvasculature vivo : prothrombin fragment 1+2 ( F1+2 ) , thrombin-anti-thrombin ( TAT ) , β-thromboglobulin ( β-TG ) , D-Dimer , thromboxane B2 ( TxB2 ) , CD40 ligand ( CD40L ) , p-Selectin . Further , endogenous thrombin potential ( ETP ) , inhibition factor Xa activity , activate partial thromboplastin time ( aPTT ) , prothrombin time ( PT ) , Biophen® Hemoclot® assess venous blood . Study population : A total 60 healthy , non-smoking drug-free male volunteer enrol trial randomize one three balance group ( treatment A , B C ; n = 20 per group ) . Main outcome variable : β-TG , F1+2 TAT shed blood Additional outcome variable : - D-Dimer , TxB2 , CD40L p-Selectin shed blood - β-TG , F1+2 , TAT , D-Dimer , TxB2 , CD40L , p-Selectin , ETP , aPTT , PT , inhibition factor Xa , Biophen® Hemoclot® venous blood Risk/ benefit assessment : Total blood loss , dependent treatment allocation , 330 ml 510 ml throughout entire study period 4 - 5 week . This amount venous blood consider acceptable healthy population . Blood sample procedure may cause mild transient pain . A minor haematoma may occur site needle insertion . Bleeding time incision may leave small persistent scar . Administration study drug , particular triple combination 5 day , result transient hypocoagulability may cause overt occult bleeding . The risk consider low healthy subject study . Continuous monitor safety parameter ( haemoglobin , haematocrit , platelet count , coagulation ) surveillance overall status perform study participation . Subjects instruct avoid vigorous physical exercise handle hazardous machinery study participation . ASA , dabigatran rivaroxaban cause gastrointestinal discomfort . Other side effect rare . The combination novel anticoagulant ( dabigatran , rivaroxaban , ticagrelor ) investigate far . Conducting study healthy population limit potential bleeding risk report drug interaction impair liver renal function , may influence pharmacokinetics -dynamics investigational product . This study provide information haemostatic system activation vivo triple treatment antithrombotic drug , indicate patient AF ACS . The result study may provide dose guidance risk reduction patient ACS AF .</brief_summary>
	<brief_title>Antithrombotic Triple Therapy Humans</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Phenprocoumon</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Healthy male subject ; 18 40 year age body mass index 18 27 kg/m2 Written inform consent Normal find medical &amp; bleed history Nonsmoking behaviour Regular intake medication include OTC drug within 2 week IMP administration Known coagulation disorder ( e.g . haemophilia , von Willebrand´s disease ) Known disorder increase bleed risk ( e.g . peridontosis , haemorrhoid , acute gastritis , peptic ulcer , intestinal ulcer ) Known sensitivity common cause bleeding ( e.g . nasal ) History thromboembolism Impaired liver function ( AST , ALT , GGT &gt; 3 x ULN , Bilirubin &gt; 2 x ULN ) Impaired renal function ( serum creatinine &gt; 1.3 mg/dl ) Any relevant deviation normal range clinical chemistry , haematology urine analysis HIV1/2Ab , HbsAg HCVAb positive serology Systolic blood pressure 100 mmHg 145 mmHg , diastolic blood pressure 95 mmHg Known allergy test agent Regular daily consumption litre xanthinecontaining beverage 40g alcohol Participation another clinical trial precede 3 week</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>